BioSpace News Archive

ViaClean Technologies, a biotech company that develops, manufactures and markets environmentally responsible solutions that protect life’s surfaces, announced the appointment of Greg Tipsord as President and Chief Executive Officer.

The U.S. Food and Drug Administration announced the following actions taken in its ongoing response effort to the COVID-19 pandemic

BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for unmet medical need, announces that bemcentinib has been selected as the first potential treatment to be fast-tracked in a new UK national multi-centre randomised Phase II clinical trial initiative

Immunomedics, Inc., a leading biopharmaceutical company in the area of antibody-drug conjugates, announced the pricing of an underwritten public offering of 14,736,860 shares of its common stock at a public offering price of $28.50 per share, representing gross proceeds of approximately $420 million.

IQVIA Holdings Inc., a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry, reported financial results for the quarter ended March 31, 2020.

MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter 2020 after the market closes on Tuesday, May 5, 2020. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Tu

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that it is now authorized by the Polish Department of Registration of

The merger CANNOT be consummated without the approval of EACH of the proposals being voted on at the Special Meeting, including approval of a reverse stock split.

Catalyst Biosciences, Inc. (NASDAQ: CBIO), a biopharmaceutical company developing novel subcutaneous (SQ) therapies for hemophilia and other bleeding disorders, today announced the European Patent Office has issued the Company a FIX portfolio patent covering the lead clinical candidate, dalcinonacog alfa (DalcA) for Factor IX (FIX) replacement therapy, and the Company’s FIX preclinical gene therapy candidate, CB 2679d-GT. “This

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel anti-infectives, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in two panels discussing antifungal and COVID-19 therapies at the upcoming Infectious Disease Virtual Conference presented by Maxim Group. Presentation Information: Panel: “Anti